US pricing at a crossroads

What will MFN pricing mean for cost, access, and patient out-of-pocket spend?

TEST lorem ipsum dolor sit amet

TEST lorem ipsum dolor sit amet

Deep Dive:

Market Access 2026

Dear Readers,

Across events and general day-to-day industry updates, one term has dominated market access conversations in 2026: Most Favoured Nation.

Now, debates over pricing in the US are nothing new – far from it. While previous administrations have made concerted efforts to curb skyrocketing out-of-pocket healthcare costs for consumers, progress in this department has been frustratingly slow. But, slow is not a word that seems to gel well with the current administration, which has adopted a far more “guns blazing” approach to driving system-wide change.

On the surface, this may seem like a positive step, however this dramatic shake-up has uncovered as many questions as it answered. So, it seemed fitting that our lead story this issue aims to unpack what MFN, and TrumpRx, actually mean for both industry and patients.

Also in this issue, we examine emerging approaches to access, including direct-to-patient and direct-to-employer models, and ask how access to innovation can be improved in the NHS.

Eloise McLennan
Deep Dive editor

Five dynasties that built modern pharma

MFN and TrumpRx: What’s the real impact for the American consumer?

The expanding role of early-phase trials in modern drug development

Can direct-to-employer models close the GLP-1 obesity care gap?

Direct-to-patient access: Five questions pharma must answer

Patient pathway activation and industry’s role in enabling access to innovation in the NHS

The GLP-1 drug revolution – and why speed alone won't save pharma

Supercharge your pharma insights: Sign up to pharmaphorum's newsletter for daily updates, weekly roundups, and in-depth analysis across all industry sectors.